Review Article

Inhaled statins to combat COVID-19 – prophylactic and treatment approach

Archana P Iyer* and Maryam A Al-Ghamdi

Published: 12 June, 2020 | Volume 4 - Issue 1 | Pages: 079-080

The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world (WHO, 2020). The genome of the SARS-CoV-2 has been reported over 80% identical to the previous human coronavirus (SARS-like bat CoV) [1]. As of May 2020, more than 5 million people have been affected worldwide with deaths amounting to 333000, the numbers increasing at an alarming rate day by day.

Read Full Article HTML DOI: 10.29328/journal.ijcv.1001020 Cite this Article Read Full Article PDF


  1. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis [published online ahead of print, 2020 Mar 31]. J Microbiol Immunol Infect. 2020; S1684-1182 (20) 30082-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/32265180/
  2. Hutchinson M, Tattersall RS, Manson JJ, Haemophagocytic lymphohisticytosis—an under recognized hyper inflammatory syndrome. Rheumatology. 2019; 58: vi23–vi30
  3. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506. PubMed: https://pubmed.ncbi.nlm.nih.gov/31986264/
  4. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet. 2020.
  5. Derebail VK, Falk RJ. ANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids. N Engl J Med. 2020; 382: 671-673. PubMed: https://pubmed.ncbi.nlm.nih.gov/32053306/


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More